Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia
Status:
Recruiting
Trial end date:
2023-08-20
Target enrollment:
Participant gender:
Summary
Patients of relapsed and refractory warm autoimmune hemolytic anemia or EVANS syndrome aged
18 to 80 will be included in this study. The treatment regimen is a single dose anti-CD20
antibody (500mg) combined with bortezomib (1.3mg/m2 twice a week for two weeks). The
treatment course would be repeated three months later.